News

Is the excitement surrounding chipmaker Nvidia fading? As of Monday, shares of the tech giant were down 19% since the start of 2025. Whether that's due to its high valuation, concerns about the

There are many dividend stocks on equity markets, but not all are attractive to income investors. Those that go beyond paying a quarterly payout but also consistently raise their dividends -- all

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). These two vaccine makers

One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that perform well tend to attract plenty of attention that bids up their share

Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022. By most standards, Pfizer looks like the

As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year. The outlook for the economy is worrisome, as trade wars and promised tariffs could lead to disaster

Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. As long as the business is still

Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key is to purchase shares of robust companies, occasionally adding more, and

In this video, I will talk about recent updates regarding Advanced Micro Devices (NASDAQ: AMD). Watch the short video to learn more, consider subscribing, and click the special offer link below.

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. I'm talking about the weight loss drug market -- one that Morgan Stanley analysts say may multiply

AT&T (NYSE: T) is often considered a slow-growth stock -- the kind of investment people hold for stable returns and dividends rather than market-beating gains. But over the past 12 months, the

Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons. The Trump administration's promised tariffs were set to go into effect the following

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol